Cited by 528Atherosclerosis and Cardiovascular DiseasesCholesterol and Lipid MetabolismAntioxidant Activity and Oxidative Stress

Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E–deficient mice

Open access
Cyrus, Tillmann, Witztum, Joseph L., Rader, Daniel J., Tangirala, Rajendra, Fazio, Sergio, Linton, MacRae F., Funk, Colin D.·1999·Journal of Clinical Investigation

Abstract

Atherosclerosis may be viewed as an inflammatory disease process that includes early oxidative modification of LDLs, leading to foam cell formation. This "oxidation hypothesis" has gained general acceptance in recent years, and evidence for the role of lipoxygenases in initiation of, or participation in, the oxidative process is accumulating. However, the relative contribution of macrophage-expressed lipoxygenases to atherogenesis in vivo remains unknown. Here, we provide in vivo evidence for the role of 12/15-lipoxygenase in atherogenesis and demonstrate diminished plasma IgG autoantibodies to oxidized LDL epitopes in 12/15-lipoxygenase knockout mice crossbred with atherosclerosis-prone apo E-deficient mice (apo E-/-/L-12LO-/-). In chow-fed 15-week-old apo E-/-/L-12LO-/- mice, the extent of lesions in whole-aorta en face preparations (198 +/- 60 microm2) was strongly reduced (P < 0.001, n = 12) when compared with 12/15-lipoxygenase-expressing controls (apo E-/-/L-12LO+/+), which showed areas of lipid deposition (15,700 +/- 2,688 microm2) in the lesser curvature of the aortic arch, branch points, and in the abdominal aorta. These results were observed despite cholesterol, triglyceride, and lipoprotein levels that were similar to those in apo E-deficient mice. Evidence for reduced lesion development was observed even at 1 year of age in apo E-/-/L-12LO-/- mice. The combined data indicate a role for 12/15-lipoxygenase in the pathogenesis of atherosclerosis and suggest that inhibition of this enzyme may decrease disease progression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci5897

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several lipoxygenases have been related to inflammation and cardiovascular disease, in particular 5-lipoxygenase and 12/15-lipoxygenase.

    “Several lipoxygenases have been related to inflammation and cardiovascular disease, in particular, 5-lipoxygenase and 12/15-lipoxygenase (203, 597, 636).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Hörkkö, S., Miller, E., Branch, D.W., Palinski, W., and Witztum, J.L. 1997. The epitopes for some antiphospholipid antibodies are adducts of oxi- dized phospholipid and beta2 glycoprotein 1. Proc. Natl. Acad. Sci. USA. 94:10356-10361.

Cited by

Sorted by citations

Authors
Cyrus, T., Witztum, J. L., Rader, D. J., Tangirala, R., Fazio, S., Linton, M. F., & Funk, C. D.
Affiliations
  • University of Pennsylvania (US)
  • University of California San Diego (US)
  • Vanderbilt University (US)
Corresponding author
Funk, Colin D.
Venue
Journal of Clinical Investigation
Published
1999-06-01
Volume
103
Issue
11
Pages
1597-1604
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2149303684
Cited by
523
References
63
Citations by year
2026: 5 · 2025: 4 · 2024: 5 · 2023: 7 · 2022: 10 · 2021: 7 · 2020: 4 · 2019: 12 · 2018: 12 · 2017: 13 · 2016: 17 · 2015: 18 · 2014: 19 · 2013: 19 · 2012: 20
FWCI
14.13
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (GM 15431)
  • National Heart, Lung, and Blood Institute (R01HL053558, R01HL059694, HL59694, HL-53558)
  • National Institute of General Medical Sciences (GM 15431, P50GM015431, P01GM015431)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Biochemistry › Antioxidant Activity and Oxidative Stress
Keywords
12/15-lipoxygenase, atherosclerosis, oxidized LDL, IgG autoantibodies, macrophages, foam cell formation, LDL oxidation, aortic lesions, atherogenesis
MeSH terms
Animals, Aorta, Apolipoproteins E, Arachidonate 12-Lipoxygenase, Arachidonate 15-Lipoxygenase, Arteriosclerosis, Autoantibodies, Female, Lipoproteins, LDL, Male, Mice, Inbred C57BL, Mice, Knockout, Lipid Metabolism, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review